Jiménez PV

Idioma: Español
Referencias bibliográficas: 20
Paginas: 203-206
Archivo PDF: 336.41 Kb.

RESUMEN

La enfermedad de Alzheimer es la forma más común de demencia. Es una enfermedad progresivamente debilitante caracterizada por daño en la memoria y deterioro funcional que es atribuido principalmente a deficiencias colinérgicas. Su larga duración,la carga de los cuidadores y los costos asociados con la atención proporcionada contribuyen a hacer de la demencia un mayor problema de salud pública. Los inhibidores de Acetilcolinesterasa: tacrina, rivastigmina, donepezilo, galantamina y memantina, son actualmente el mejor tratamiento establecido para esta devastante enfermedad. Conclusión: Aunque estas drogas no son la cura pueden retrasar el progreso del deterioro mental, reducir los síntomas neuropsiquiatricos y por lo tanto, representar un enfoque terapéutico racional para el tratamiento de la enfermedad de Alzheimer.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Blesa R, Garcia G, Gladós L, Olascoaga J, Amer G, MareyJ et al. Estudio observacional sobre seguridad tolerabilidad y efectividad de la galantamina en pacientes con enfermedad de Alzheimer leve a moderamente grave. Neurología 2006; 20:289-296.

2. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer’s disease. Int J Geriatry Psychiatry 2004; 19, 243-249.

3. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere j, Bourdeix I. Rivastigmine monotherapy and combination therapy with memeantine in patients with moderately severe Alzheimer`s disease who failed to benefit from previous cholinesterase Inhibitor treatment. Int J Clin Pract. 2006:60(1):110-118.

4. Ibach B, Haen E. Acetylcholinesterase Inhibition in Alzheimer’s disease. Curr Pharm Design 2004; 10:231-251.

5. Jones R. Have cholinergic therapies reached their clinical boundary in Alzheimer’s disease. Int J Geriat Psychiatry 2003; 18:7-13.

6. Lahiri D, Rogersa J, Greig N, Sambamurti K. Rationale for the development of cholinesterase Inhibitors as anti-Alzheimer agents. Curr Pharm Design 2004, 10:3111-3119.

7. Levy M, Cummings J, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology. 1999; 45:15-22.

8. Malaguarnera M, Pistone G, Vinci M, Motta M, Fazio I, Rampello L. Tacrine treatment of Alzheimer`s disease: many expectations, few certainties. Neuropsychobiology 1998; 38:226-231.

9. Monczor M. Diagnosis and Treatment of Alzheimer’s disease. Curr Med Che - Central Nervous System Agents 2005; 5:5-13.

10. Morales J, Gutiérrez L. Epidemiología de las demencias. Arch Neurocien (Mex) 2006; 11:3-13.

11. Olsen C, Poulsen H, Lublin H. Drug therapy of dementia in elderly patients. A review. Nord J Psychiatric 2005; 59:71-77.

12. Ott B, Lapane K. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002; 50:35-40.

13. Sano M, Wilcock G, Van Baelen B, Kavanagh S. The effects of galantamine treatment on caregiver time in Alzheimer’s disease. Int J Geriatr Psychiatry 2003; 18:942-950.

14. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Pyne E, Gren C. A systematic review of the clinical effectiveness of donepezil, rivastigmine ando galantamine on cognition, quality of life and adverse events in Alzheimer`s disease. Int J Geriatr Paychiatry 2006; 21:17-28.

15. Tomita N, Ootsuki M, Maruyama M, Matsui T, Higuchi M, Tsutsui M et al. Long-term cognitive benefits of donepezil in Alzheimer’s disease: Aretrospective comparison between 1994-1999 and 2000-2004. Geriatr Gerontol Int 2007; 7:41-47.

16. Villarroya M, García A, Marco J. New Classes of AChE Inhibitors with Additional Pharmacological Effects of Interest for the Treatment of Alzheimer’s disease. Curr Pharm Design 2004; 10:3177-3184.

17. Wilkinson D, Howe I. Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Int J Geriatr Psychiatry 2005; 20:489-491.

18. Winblad B, Cummings J, Andreasen J, Grossberg G, Onofrj M,Sadowsky C. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer`s disease- rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22:456-467.

19. Winblad B, Kawata A, Beusterien K, Thomas S, Wimo A, Lane R, et al. Caregiver preferente for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22:485-491.

20. Winblad B, Kilander L, Eriksson S. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367:1057-1065.